Zydus Lifesciences Ltd has received final approval from the United States Food and Drug Administration to manufacture and market Roflumilast Tablets, 250 mcg.
On Wednesday, 1811 stocks advanced, 1701 declined and 122 remained unchanged on the Bombay Stock Exchange (BSE), with an advance decline ratio of 1.06, indicating a positive closing of stocks in broader markets.